Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CHIMERIX INC (CMRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Investor presentation, Quarterly results
Docs: "Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update – Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries&#59; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –",
"Chimerix Corporate Presentation August 3, 2023 2 Forward-Looking Statements This"
03/02/2023 8-K Investor presentation, Quarterly results
Docs: "Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update – Continued Execution and Progress Towards Commercial Approval of Dordaviprone with Global Launch of Phase 3 ACTION Study –",
"2 Forward-Looking Statements This"
08/08/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update – Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma –",
"Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma – Blinded Independent Central Review of ONC201 Cohort Reported 20.0% Objective Response Rate by RANO-HGG Criteria –"
08/05/2021 8-K Quarterly results
Docs: "Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update – Received U.S. Food and Drug Administration Approval for TEMBEXA® for the Treatment of Smallpox –"
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Chimerix Reports Third Quarter 2020 Financial Results and Provides Operational Update – Completed Rolling NDA Submissions for Both BCV Tablet and Suspension Formulations as Medical Countermeasure for Smallpox –"
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "CHIMERIX, INC. CONSOLIDATED BALANCE SHEETS ASSETS"
08/08/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "Chimerix Announces First Quarter 2019 Financial Results and Strategy Update - Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission - - Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir Development Activities - - Restructuring to Reduce Workforce by More Than 50%, Maintaining Key Capabilities and Preserving Capital for New Programs - - Conference Call at 8:30 a.m. ET Today -"
11/08/2018 8-K Quarterly results
Docs: "Chimerix Announces Third Quarter 2018 Financial Results - Conference Call at 8:30 a.m. ET Today -"
08/08/2018 8-K Quarterly results
Docs: "Chimerix Announces Second Quarter 2018 Financial Results - Conference Call at 8:30 a.m. ET Today -"
05/07/2018 8-K Quarterly results
Docs: "Chimerix Announces First Quarter 2018 Financial Results - Landmark AdVance Study Demonstrates Strong Correlation Between Adenovirus Burden and Mortality Risk - - Site Initiations for AdAPT Study of Oral Short-course Brincidofovir for Adenovirus and IV Brincidofovir Programs Are Progressing - - First Presentation on CMX521 for Norovirus in June - - Conference Call at 8:30 a.m. ET Today -"
11/08/2017 8-K Quarterly results
Docs: "Chimerix Announces Third Quarter 2017 Financial Results - Conference Call at 8:30 a.m. ET Today -"
08/07/2017 8-K Quarterly results
Docs: "Chimerix Announces Second Quarter 2017 Financial Results - Conference Call at 8:30 a.m. ET Today -"
05/09/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Chimerix Announces Third Quarter 2016 Financial Results"
02/29/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Chimerix Announces Third Quarter 2015 Financial Results Topline Data from SUPPRESS Trial of Brincidofovir for Prevention of Cytomegalovirus in Hematopoietic Cell Transplant Recipients Anticipated in Early 2016 Dosing Initiated in Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients"
08/06/2015 8-K Quarterly results
Docs: "Chimerix Announces Second Quarter 2015 Financial Results Targeted Enrollment Now Completed for Brincidofovir SUPPRESS and AdVise Trials Statistically Significant Survival Benefit Demonstrated in Brincidofovir Pivotal Study in Animal Model of Smallpox Infection"
05/11/2015 8-K Quarterly results
Docs: "Chimerix Announces First Quarter Financial Results Company Plans to Initiate Brincidofovir SURPASS and SUSTAIN Studies in Kidney Transplant Recipients in Second Half 2015"
03/06/2015 8-K Quarterly results
Docs: "Chimerix Announces Fourth Quarter and Full Year 2014 Financial Results"
11/07/2014 8-K Quarterly results
Docs: "Chimerix Announces Third Quarter 2014 Financial Results"
08/07/2014 8-K Quarterly results
Docs: "Chimerix Announces Second Quarter 2014 Financial Results"
05/09/2014 8-K Quarterly results
Docs: "Chimerix Announces First Quarter 2014 Financial Results"
03/07/2014 8-K Quarterly results
Docs: "Chimerix Announces Fourth Quarter and Full Year 2013 Financial Results"
11/14/2013 8-K Quarterly results
Docs: "Chimerix Announces Third Quarter 2013 Financial Results"
08/14/2013 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy